- Home
- URGN vs DBI Comparison
URGN vs DBI Comparison
Compare URGN & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- DBI
- Stock Information
- Founded
- URGN 2004
- DBI 1991
- Country
- URGN United States
- DBI United States
- Employees
- URGN N/A
- DBI N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- DBI Clothing/Shoe/Accessory Stores
- Sector
- URGN Health Care
- DBI Consumer Discretionary
- Exchange
- URGN Nasdaq
- DBI Nasdaq
- Market Cap
- URGN 547.1M
- DBI 453.2M
- IPO Year
- URGN 2017
- DBI 1991
- Fundamental
- Price
- URGN $12.84
- DBI $6.26
- Analyst Decision
- URGN Strong Buy
- DBI Hold
- Analyst Count
- URGN 5
- DBI 3
- Target Price
- URGN $44.50
- DBI $6.50
- AVG Volume (30 Days)
- URGN 764.9K
- DBI 2.6M
- Earning Date
- URGN 11-12-2024
- DBI 12-03-2024
- Dividend Yield
- URGN N/A
- DBI 3.19%
- EPS Growth
- URGN N/A
- DBI N/A
- EPS
- URGN N/A
- DBI N/A
- Revenue
- URGN $85,011,000.00
- DBI $3,059,173,000.00
- Revenue This Year
- URGN $16.49
- DBI $0.78
- Revenue Next Year
- URGN $57.58
- DBI $3.19
- P/E Ratio
- URGN N/A
- DBI N/A
- Revenue Growth
- URGN 17.22
- DBI N/A
- 52 Week Low
- URGN $10.60
- DBI $4.36
- 52 Week High
- URGN $20.70
- DBI $12.84
- Technical
- Relative Strength Index (RSI)
- URGN 49.60
- DBI 47.05
- Support Level
- URGN $11.84
- DBI $5.68
- Resistance Level
- URGN $13.54
- DBI $6.27
- Average True Range (ATR)
- URGN 0.82
- DBI 0.34
- MACD
- URGN 0.08
- DBI -0.02
- Stochastic Oscillator
- URGN 65.88
- DBI 32.58
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment, and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.